For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-nano-chemotherapy-market-and-clinical-trials-outlook-2022.php
Table of Contents
-
Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential
-
Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles
-
Role of Nanotherapeutics in Various Diseases Treatment
3.1 Nanotherapeutics Approach for Cardiovascular Disease
3.2 Nanotherapeutics Approach for Cancer Therapy
3.3 Nanotherapeutics Approach for Diabetes Treatment
3.4 Nanotherapeutics Approach for Rheumatoid Arthritis
-
Chemotherapeutics Nanoformulations of Approved Drugs: Clinical Insights and Price Analysis
4.1 Abraxane (Advanced Lung, Pancreatic, Breast Cancers)
4.2 Depocyte (Lymphomtous Meningitis)
4.3 Doxil (Kaposi’s Sarcoma, Ovarian Cancer)
4.4 Marqibo (Acute Myelogenous Leukemia)
4.5 Neulasta (Chemotherapy Induced Neutropenia)
4.6 Oncospar (Acute Lymphoblastic Leukemia)
4.7 Zevalin (Non-Hodgkin Lymphoma)
-
Chemotherapeutics Nanoformulations in Clinical Trials: Clinical Insight and Mode of Action
5.1 MM-302 (Metastatic Breast Cancer)
5.2 Thermodox (Hepatobiliary Tumors)
5.3 CPX-351 (Acute Myelogenous Leukemia)
5.4 IHL-305 (Solid Tumor Malignancy)
5.5 MM-398 (Metastatic Pancreatic Cancer)
5.6 BIND-014 (Metastatic Prostate Cancer)
5.7 NK-012 (Solid Tumor Malignancy)
5.8 CRLX-101 (Solid Tumor Malignancy and Rectal Cancer)
-
Global Market Nanotherapeutics Outlook
6.1 Market Scenario of Nanotherapeutics
6.2 Market Size of Nanomedicine
-
Cancer Nanotherapeutics Market Revenue
7.1 Sales of Nano Chemotherapeutic Drugs
7.2 Top Nanotherapeutics Companies Revenue
7.3 Global Cancer Nanomedicine Clinical Pipeline Overview
-
Global Nano Chemotherapeutics Market Dynamics
8.1 Favorable Parameters
8.2 Challenges to the Market Growth
-
Future Perceptive of Nano Chemotherapeutics
-
Competitive Landscape
10.1 Ablynx
10.2 AMAG
10.3 Amgen
10.4 Celgene
10.5 CytImmune
10.6 Cornerstone
10.7 Delpor
10.8 Ensysce
10.9 MagForce AG
10.10 Merrimack
10.11 Nanotherapeutics
10.12 Nanobiotix
10.13 Nanospectra
10.14 Spectrum pharmaceuticals
10.15 Tarveda
Figure 1-1: Application of Nanotechnology in the Field of Medicine
Figure 1-2: Biomedical Application of Nano chemotherapeutics
Figure 1-3: Nano Chemotherapeutics with Pharmaceutical Potential
Figure 2-1: Limitations to Conventional Chemotherapy Treatment
Figure 3-1: Nanotherapeutics for Heart Disease Treatment
Figure 3-2: Nanotherapeutics Approach in Cancer Therapy
Figure 3-3: Nanotherapeutics Approach for Diabetes Treatment
Figure 3-4: Rheumatoid Arthritis Treatment by Nanotherapeutics
Figure 4-1: Abraxane – Market Price (US$ per Unit Injection) and Patent Expiration Year
Figure 4-2: Cytarabine – Market Price for 20 mg/ml and 100 mg/ml (US$)
Figure 4-3: Doxil and Doxorubicin – Price of Intravenous Solution (US$)
Figure 4-4: Marqibo – Price of Intravenous Solution (US$) and Patent Expiration Year
Figure 4-5: Neulasta – Price for 6 mg/ 0.6 ml and Per Unit Cost (US$)
Figure 4-6: Oncospar – Price for 750 Units/ml and for Per Unit Cost (US$)
Figure 4-7: Zevalin – Price of Intravenous Solution (US$) and Patent Expiration Year
Figure 5-1: Mechanism of Action of MM-302
Figure 5-2: Mechanism of Action of Thermodox and its Mechanical Release
Figure 5-3: Future Development of CPX-351
Figure 5-4: Outsourcing for BIND-014 Clinical Supplies
Figure 5-5: Structure of NK-012 and Release of SN-38 from NK-012
Figure 5-6: Design of a Clinical Trial for CRLX-101
Figure 6-1: Global – Nanomedicine Market (US$ Billion), 2016-2022
Figure 7-1: Sales of Nano Chemotherapeutic Sales (US$, Million), 2016
Figure 7-2: Nano Chemotherapeutics Companies Sales Revenue (US$, Million), 2015
Figure 7-3: Global – Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 7-4: Global – Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 7-5: Global – Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 7-6: Global – Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-1: Favorable Parameters to Nano Chemotherapeutic Market
Figure 8-2: Challenges to Nano chemotherapeutics Market Growth
Figure 9-1: Future Development Opportunities of Nanomedicine
Table 3-1: Adverse Reactions with andge; 5% Higher Incidence in Neulasta Patients Compared to Placebo